ArticleFrontiers in oncology2026
A pathological classification for predicting recurrence and guiding adjuvant therapy in esophageal squamous cell carcinoma following neoadjuvant immunochemotherapy: a two-center cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant immunochemotherapy (nICT) has emerged as a promising treatment modality for locally advanced esophageal squamous cell carcinoma (ESCC). However, optimal post-nICT adjuvant strategies remain undefined, and a classification system that integrates both prognosis and recurrence patterns to guide treatment decisions is currently lacking. Methods: This retrospective study enrolled 283 patients with locally advanced ESCC who underwent nICT with R0 resection between January 2019 and December 2023 at two participating institutions. The primary endpoint was recurrence-free survival (RFS). Secondary endpoints included recurrence patterns, overall survival (OS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS). Survival curves were generated using the Kaplan-Meier method. Propensity score matching was employed for group comparisons and a Cox proportional hazards model was used to identify prognostic factors. Results: The pathological complete response (pCR) and major pathological response (MPR) rates were 22.6% and 52.3%, respectively. Multivariate analysis identified the tumor regression grade (TRG) and ypN stage as independent predictors of RFS. Both ypN status and TRG were key determinants of recurrence patterns. Based on this, patients were stratified into four subgroups: Group 1 (TRG0-1 ypN0), Group 2 (TRG0-1 ypN+), Group 3 (TRG2-3 ypN0), and Group 4 (TRG2-3 ypN+). This classification demonstrated significant prognostic stratification, with Group 1 having the best prognosis and Group 4 having the worst prognosis. In the entire matched cohort, adjuvant therapy did not significantly improve survival. However, subgroup analyses revealed that adjuvant therapy was associated with a significant improvement in RFS in Group 2 (TRG0-1 ypN+)(HR = 0.16, 95% CI 0.06-0.42, Conclusion: The proposed classification system based on TRG and ypN status effectively stratified the prognosis of patients with ESCC after nICT. This classification enabled the identification of a specific subgroup (TRG0-1 ypN+) that may benefit from postoperative adjuvant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.